NIH: mRNA vaccine generates immune response in older adults

An experimental mRNA vaccine for the COVID-19 virus generated a strong immune response in older adults in a phase 1 clinical trial, who generally tolerated it well, the National Institutes of Health reports.
The National Institute of Allergy and Infectious Diseases developed the vaccine with Moderna Inc.
The phase 1 trial began in March and later added 40 healthy adults over age 55, who received two doses and will be followed for a year to monitor the long-term effects of the vaccine. According to the researchers, the results support testing the vaccine in older adults in an ongoing large Phase 3 trial.
Related News Articles
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…